

KADCYLA: A different kind of treatment for HER2-positive metastatic breast cancer has emerged

Who is KADCYLA for?

KADCYLA is approved to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.

Please see KADCYLA full Prescribing Information, including



What is the most important safety information I should know about KADCYLA?



KADCYLA is not the same medicine as trastuzumab (Herceptin)



Liver problems

- KADCYLA may cause severe liver problems that can be life-threatening. Symptoms of liver problems may include vomiting, nausea, eating disorder (anorexia), yellowing of the skin (jaundice), stomach pain, dark urine, or itching



Heart problems

- KADCYLA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ankles or legs, shortness of breath, cough, rapid weight gain of greater than 5 lbs in less than 24 hours, dizziness or loss of consciousness, or irregular heartbeat



Pregnancy

- Receiving KADCYLA during pregnancy can result in the death of an unborn baby and birth defects. Birth control should be used while you receive KADCYLA and for 6 months after your last dose of KADCYLA
- If you are exposed to KADCYLA during pregnancy, contact your healthcare provider right away; you are also encouraged to enroll in the MoTHER Pregnancy Registry by calling 1-800-690-6720
- If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping KADCYLA

Contact your doctor right away if you experience symptoms associated with these side effects.

Please see KADCYLA full Prescribing Information, including Most Important Safety

Table of contents

Understanding your type of cancer	4
How KADCYLA is different	6
KADCYLA may help you live longer.....	8
Getting started with KADCYLA	10
Additional side effects with KADCYLA	12
Getting support during treatment.....	14
Questions to ask your doctor or nurse	17
Glossary.....	18

Additional Possible Serious Side Effects include:

- Lung problems
- Infusion-related reactions
- Serious bleeding
- Low platelet count
- Nerve damage
- Skin reactions around infusion site

For more information on these side effects, please see pages 12-13.

About this brochure

Living with HER2-positive metastatic breast cancer is hard. Your healthcare team may have given you a lot of information on treatment options.

This brochure explains treatment with KADCYLA and how it may help you.

The information in this brochure should not replace the advice of your healthcare team. If you have questions about your treatment, be sure to talk with your doctor or nurse.



Understanding your type of cancer

HER2 receptor:

A type of protein that is found on the surface of cells in everyone. This protein tells cells to grow and divide. Too much HER2 is called "HER2 overexpression."

HER2-positive or HER2+:

Breast cancer cells that have too many HER2 receptors.


Metastatic breast cancer:

Breast cancer that has spread to other parts of the body, such as the lungs, liver, or bones.

What is HER2-positive metastatic breast cancer?

Both normal cells and cancer cells have **HER2 receptors**. In **HER2-positive metastatic breast cancer**, cancer cells have more HER2 receptors than normal cells.

- Too many HER2 receptors on cancer cells makes this type of cancer grow faster



Please see KADCYLA full Prescribing Information, including Most Important Safety

What HER2-targeted treatments do

HER2-targeted treatments are designed to attack cells that have HER2 receptors. The treatments bind to the HER2 receptors on your cells. If you have HER2-positive metastatic breast cancer, you may be able to take HER2-targeted treatments.

- KADCYLA, Herceptin (trastuzumab), and Tykerb® (lapatinib) are types of HER2-targeted treatments discussed in this brochure

How will my doctor know if KADCYLA is right for me?

You must have a HER2 test to determine if your cancer is HER2 positive before taking KADCYLA, because benefit has been shown only in patients whose tumors are HER2 positive.



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.